Black Diamond Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Black Diamond Therapeutics

03/11/2023 18:15

* Black Diamond Therapeutics Inc  BDTX.OQ   BDTX.O  is
expected
to show no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Black Diamond
Therapeutics Inc is for a loss of 49 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Black
Diamond
Therapeutics Inc is $10.5​, above​ its last closing price
of $1.80. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.54       -0.54      -0.52     Beat    3
 Mar. 31 2023  -0.61       -0.61      -0.57     Beat    6.2
 Dec. 31 2022              -0.63      -0.59     Beat    6​
 Sep. 30 2022  -0.64       -0.64      -0.60     Beat    6.3
 ​​Jun.        -0.69       -0.68      -0.63     Beat    7.4
 30 2022                                                
 Mar. 31 2022  -0.78       -0.75      -0.70     Beat    6.8​
 Dec. 31 2021              -1.01      -0.71     Beat    29.9
 Sep. 30 2021  -0.98       -0.98      -0.97     Beat    0.9
 This summary was machine generated November 3 at 18:14 GMT.  All
figures in US dollars  unless otherwise stated